S. Workenhe

发表

Absolute quantitation of infectious salmon anaemia virus using different real-time reverse transcription PCR chemistries

T. Iwamoto, F. Kibenge, S. Workenhe, 2008, Journal of Virological Methods.

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning

G. Kroemer, S. Workenhe, B. Lichty, 2020, Journal for ImmunoTherapy of Cancer.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

L. Zitvogel, L. Galluzzi, G. Kroemer, 2018, Oncoimmunology.

TRIM26 Facilitates HSV-2 Infection by Downregulating Antiviral Responses through the IRF3 Pathway

S. Workenhe, Aisha Nazli, C. Kaushic, 2021, Viruses.

Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy

S. Workenhe, B. Lichty, Jonathan G. Pol, 2013, Cancer Immunology Research.

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

W. Halford, S. Workenhe, B. Lichty, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis

J. Diallo, N. Sonenberg, T. Alain, 2018, PLoS pathogens.

Infectious salmon anaemia virus (ISAV) isolates induce distinct gene expression responses in the Atlantic salmon (Salmo salar) macrophage/dendritic-like cell line TO, assessed using genomic techniques.

F. Kibenge, M. Rise, S. Workenhe, 2009, Molecular immunology.

Viral-mediated activation and inhibition of programmed cell death

S. Workenhe, Shayla Grace Verburg, Rebecca Margaret Lelievre, 2022, PLoS pathogens.

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

S. Workenhe, K. Mossman, 2013, Oncoimmunology.

Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes

F. Kibenge, S. Workenhe, M. Kibenge, 2008, Virology Journal.

Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer

D. Roy, J. Bell, S. Workenhe, 2019, Scientific Reports.

LAMP3/CD63 Expression in Early and Late Endosomes in Human Vaginal Epithelial Cells Is Associated with Enhancement of HSV-2 Infection

C. Verschoor, S. Workenhe, Aisha Nazli, 2022, Journal of virology.

Countermeasures against viral diseases of farmed fish.

F. Kibenge, M. Fast, S. Workenhe, 2012, Antiviral research.

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

S. Workenhe, Jonathan G. Pol, J. Bramson, 2018, Cell reports.

The fight between the teleost fish immune response and aquatic viruses.

F. Kibenge, M. Rise, S. Workenhe, 2010, Molecular immunology.

Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies

S. Wootton, S. Workenhe, K. Mossman, 2018, The Journal of Immunology.

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells

B. Nelson, K. Milne, A. Ashkar, 2021, Communications Biology.

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells

B. Nelson, K. Milne, A. Ashkar, 2021, Communications biology.

Consensus guidelines for the detection of immunogenic cell death

P. Vandenabeele, S. Loi, L. Zitvogel, 2014, Oncoimmunology.

Cytokines in oncolytic virotherapy.

G. Kroemer, S. Gujar, S. Workenhe, 2020, Cytokine & growth factor reviews.

Genetic modification of oncolytic viruses to enhance antitumor immunity.

S. Workenhe, K. Mossman, A. Vito, 2020, Methods in enzymology.

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

S. Workenhe, K. Mossman, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Structural and functional studies of an IRF-7-like gene from Atlantic salmon.

S. Workenhe, B. Robertsen, Veronica Bergan, 2009, Developmental and comparative immunology.

Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells

J. Moffat, T. Ketela, K. Mossman, 2016, Oncogene.

Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype

K. Mossman, S. Workenhe, A. Dyer, 2013, Cancer Gene Therapy.

The role of oncolytic virus immunotherapies to subvert cancer immune evasion.

S. Workenhe, K. Mossman, M. Verschoor, 2015, Future oncology.

De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors

Jalees A. Nasir, A. Oberst, D. Bakhshinyan, 2020, Communications Biology.

Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer

D. Roy, J. Bell, S. Workenhe, 2019, Scientific Reports.

Tumor-intrinsic determinants of immunogenic cell death modalities

G. Kroemer, S. Workenhe, Jonathan G. Pol, 2021, Oncoimmunology.

A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner

S. Workenhe, K. Mossman, Y. Wan, 2022, International journal of molecular sciences.

Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1

S. Workenhe, Aida Said, Huy-Dung Hoang, 2023, Journal for ImmunoTherapy of Cancer.

Determinants for Antitumor and Protumor Effects of Programmed Cell Death

S. Workenhe, Jordon M Inkol, Shayla G Verburg, 2023, Cancer immunology research.